Japan

Ribomic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

RIBOMIC Enters License Agreement with AJU Pharma

Lead Product(s): RBM-007

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: AJU Pharma

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 17, 2020

Details:

Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory.

Santen Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

Santen, Tracon discontinue development of eye drug after mid-stage trial failure

Lead Product(s): Carotuximab

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

The companies said DE-122, when combined with Lucentis, did not meet the trial's main goal of improving visual acuity in patients with wet AMD compared to those taking Lucentis alone.

Ribomic

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

ASCO 2020

Participation Not Confirmed

Update your events

RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)

Lead Product(s): RBM-007,Aflibercept

Therapeutic Area: Ophthalmology

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 19, 2020

Details:

First patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

Ribomic

RIBOMIC Enters License Agreement with AJU Pharma

Santen Pharmaceutical

Santen, Tracon discontinue development of eye drug after mid-stage trial failure

Ribomic

RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study)